ISSN 2398-2942      

Rabacfosadine

icanis

Synonym(s): Tanovea-CA1


Introduction

Name

  • Rabacfosadine.

Class of drug

  • Anti-neoplastic.

Description

Chemical name

  • 9-(2 -phosphonylmethoxyethyl)-N6 -cyclopropyl-2,6-diaminopurine (cPrPMEDAP). 

Molecular formula

  • C21H35N8O6P

Molecular weight

  • 526.5 

Physical properties

  • White to off-white lyophilized powder in the form of a cake contained in a 3 mL amber glass vial.  

Storage requirements

  • Unopened vials: store the vials refrigerated at 2° to 8°C (36° to 46°F). Retain in original package to protect from light. Store in a dark, dry, cool area.
  • After reconstitution with 2 mL of 0.9% sodium chloride: store at 20° to 25°C (68° to 77°F). TANOVEA-CA1 should be diluted for infusion within 4 hours of reconstitution. The infusion solution should be used within 24 hours of being added to infusion bag or syringe and within 4 hours of attachment to an intravenous administration set. Protection from light not needed. 

Uses

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Indications

  • For the treatment of lymphoma Lymphoma in dogs.  

Administration

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Pharmacokinetics

Precautions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Interactions

With other drugs

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Further Reading

Publications

Refereed Papers

  • Recent references from PubMed and VetMedResource.
  • Cawley J R, Wright Z M, Meleo K, Post G S, Clifford C A, Vickery K R, Vail D M, Bergman  P.J. Thamm D H (2020) Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. J Vet Int Med 34 (2), 882-889 PubMed.
  • Saba C F, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post  G, Thamm D (2020) Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Vet Comp Oncol 18 (4), 763-769 PubMed.
  • DeClercq E (2018) Tanovea for the treatment of lymphoma in dogs. Biochem Pharmacol 154, 265-269 PubMed.
  • Saba C F, Vickery K R, Clifford C A, Burgess K E, Phillips B, Vail D M, Wright Z M, Morges M A, Fan T M, Thamm D H (2018) Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol 16(1),  E76-E82 PubMed
  • Thamm D H, Vail D M, Post G S, Fan T M, Phillips B S, Axiak‐Bechtel S, Elmslie R S, Klein M K, Ruslander D A (2017) Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. J Vet Intern Med 31 (3), 872-878 PubMed.
  • Veterinary Cooperative Oncology Group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol (2016) DOI: 10.1111/vco.283 PubMed
  • Morges M A, Burton J H, Saba C F, Vail D M, Burgess K E, Thamm D H (2014) Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. J Vet Intern Med 28(5), 1569-1574 PubMed
  • Thamm D H, Vail D M, Kurzman I D et al (2014) GS-9219/VDC-1101-a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. BMC Vet Res 10, 30 PubMed
  • Vail D M, Thamm D H, Reiser H, Ray A S, Wolfgang G H I, Watkins W J, Babusis D, Henne I N, Hawkins M J, Kurzman I D, Jeraj R, Vanderhoek M, Plaza S (2009) Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 15(10), 3503-3510 PubMed
  • Therasse P, Arbuck S G, Eisenhauer E A, Wanders J, Kaplan R S, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom A T, Christian M C, Gwyther S G (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 205-216 PubMed
  • Reiser H, Wang J Y, Chong L et al (2008) GS-9219/VDC-1101—a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma. Clin Cancer Res 14(9),2824-2832 PubMed.

Other sources of information

MEMBER BENEFIT

Can’t find what you’re looking for?

We have an ever growing content library on Vetlexicon so if you ever find we haven't covered something that you need please fill in the form below and let us know!

 
 
 
 

To show you are not a Bot please can you enter the number showing adjacent to this field

 Security code